Drug Search Results
More Filters [+]

PF-06473871

Alternative Names: pf-06473871, pf06473871, pf 06473871
Latest Update: 2021-08-13
Latest Update Note: Clinical Trial Update

Product Description

The antisense oligonucleotide, PF-06473871, comprises a 20-nucleotide chain containing a phosphorothioate backbone and 2Õ-methoxyethyl modifications of the ribose units at the 3Õ and 5Õ ends, conferring resistance to nucleases and providing long residence in tissues. PF-06473871 targets CTGF expression and is delivered by intradermal injection to a surgical wound. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191237/)

Mechanisms of Action: CTGF Inhibitor

Novel Mechanism: Yes

Modality: Nucleic Acid

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PF-06473871

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Healthy Volunteers|Vision, Low|Other

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

B5301012

P2

Terminated

Vision, Low

2015-01-01

2012-004355-37

P2

Completed

Unknown

2014-10-17

B5301001

P2

Completed

Healthy Volunteers

2014-10-01

EXC 001-206

P2

Completed

Other

2013-09-10

Recent News Events

Date

Type

Title